Compare LBRDP & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDP | VERA |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | LBRDP | VERA |
|---|---|---|
| Price | $24.24 | $46.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $76.60 |
| AVG Volume (30 Days) | N/A | ★ 1.5M |
| Earning Date | N/A | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $18.53 |
| 52 Week High | N/A | $56.05 |
| Indicator | LBRDP | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 51.87 |
| Support Level | $24.02 | $47.22 |
| Resistance Level | $24.41 | $56.05 |
| Average True Range (ATR) | 0.19 | 2.32 |
| MACD | -0.04 | -1.22 |
| Stochastic Oscillator | 34.07 | 8.63 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.